Realizing Chemotherapy as a Therapeutic Option for Prostate Cancer

Dr. Thomas Buckley (2002 Research Grant)

Although, chemotherapy is a popular cancer therapy, it is not as effective for prostate cancer. Chemotherapy is also harmful to healthy cells. As a result, it is not a popular treatment for prostate cancer. In 2002 we granted Dr. Thomas Buckley funds to research a prostate cancer-specific toxin. His work has been very successful; he has developed a drug called PRX302 which selectively and effectively kills PSA-producing cells without harming other tissues.

The results of the initial study were so encouraging that a company, called Protox Therapeutics, was formed to further develop the idea and hopefully bring the discovery to market. The drug is now in phase II clinical trails.




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More

12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More


Click here for news archive